HARMONY BIOSCIENCES HOLDINGS (HRMY) Stock News
NASDAQ:HRMY - Nasdaq - US4131971040 - Common Stock - Currency: USD
HRMY Latest News, Press Relases and Analysis
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Potentially Undervalued Stock with Strong Fundamentals
Harmony Biosciences (HRMY) shows strong growth, profitability, and financial health while trading at an attractive valuation, making it a potential pick for value investors.
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) - A Strong Candidate for Affordable Growth Investors
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) offers strong growth, reasonable valuation, and solid financial health, making it an attractive option for investors seeking affordable growth stocks.
Deep Dive Into Harmony Biosciences Hldgs Stock: Analyst Perspectives (13 Ratings)
Harmony Biosciences Holdings, Inc. (HRMY) Tops Q1 Earnings and Revenue Estimates
Harmony Biosciences (HRMY) delivered earnings and revenue surprises of 32.20% and 0.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: SWTX
Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance
Exploring the Growth Potential of HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) as It Nears a Breakout.
Based on fundamental and technical analysis of NASDAQ:HRMY we ask: Why HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) Is a Standout High-Growth Stock in a Consolidation Phase.
Why Harmony Biosciences (HRMY) Could Beat Earnings Estimates Again
Harmony Biosciences (HRMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know
Cue Biopharma (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: CUE
Jim Cramer on Micron (MU): “No Catalyst, But You’re Buying Near the Low End”
We recently published a list of Jim Cramer Recently Discussed These 9 Stocks. In this article, we are going to take a look at where Micron Technology, Inc. (NASDAQ:MU) stands against other stocks that Jim Cramer discussed recently. Jim Cramer, the host of Mad Money, discussed the current economic outlook on Monday as he outlined […]
Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025
Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome
Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors
Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference
Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands
HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY)....
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY)....
Harmony Biosciences to Participate in Upcoming Investor Conferences
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY)....
Harmony Biosciences (HRMY) Q4 2024 Earnings Call Transcript
HRMY earnings call for the period ending December 31, 2024.
